Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study

2003 ◽  
Vol 7 (5) ◽  
pp. 543-546 ◽  
Author(s):  
H Mousavi Fatemi ◽  
E Kolibianakis ◽  
H Tournaye ◽  
M Camus ◽  
AC Van Steirteghem ◽  
...  
Keyword(s):  
Pilot Study ◽  
Ovarian Stimulation ◽  
Clomiphene Citrate

scholarly journals Women’s Reports of Barriers to and Facilitators of Oral Medication Adherence During Ovarian Stimulation: A Mixed Methods Pilot Study

2021 ◽  
Author(s):  
Diane E. Mahoney ◽  
Cynthia L. Russell
Keyword(s):  
Mixed Methods ◽  
Medication Adherence ◽  
Pilot Study ◽  
Ovarian Stimulation ◽  
Lifestyle Modification ◽  
Intrauterine Insemination ◽  
Clomiphene Citrate ◽  
Oral Medication ◽  
Fertility Treatment ◽  
Daily Routine

Background: Adherence to lifestyle modification recommendations remains problematic for women undergoing fertility treatment, raising concerns about the extent to which women adhere to prescribed medication regimens. Limited data have shown suboptimal oral medication adherence rates of 19% to 74%. The objective of this study was to explore what women perceive as barriers to and facilitators of oral medication adherence during fertility treatment cycles. Methods: An exploratory mixed methods pilot study was conducted among a sample of 30 women who were actively taking one to two cycles of letrozole or clomiphene citrate for ovarian stimulation in conjunction with intrauterine insemination cycles. Medication adherence barriers were measured using a 20-item survey. Medication adherence facilitators and personal experiences with fertility treatment were assessed with structured interviews. Medication adherence was assessed with electronic event monitoring.  Results: The overall medication adherence median was 0.97 with a range of 0.75 to 1.00, and nine women (50%) demonstrated perfect adherence. The most commonly reported barriers were recently feeling sad, down, or blue (53%), and taking medication more than once per day (40%). Women with higher barrier scores had significantly lower medication adherence scores (p=0.02) compared to women with lower total barrier scores. Facilitators included using physical aides as reminders (60%) and establishing a daily routine (50%). No significant correlation was found between medication adherence scores and facilitators.  Conclusion: The dynamic interplay between perceived barriers and facilitators and women’s medication-taking patterns could influence whether or not medication regimens are followed correctly.

Effects of controlled ovarian stimulation on vascular barrier and endothelial glycocalyx a pilot study

2020 ◽  
Author(s):  
N Rogenhofer ◽  
N Hulde ◽  
F Brettner ◽  
I Götzfried ◽  
JI Buchheim ◽  
...  
Keyword(s):  
Pilot Study ◽  
Ovarian Stimulation ◽  
Controlled Ovarian Stimulation ◽  
Endothelial Glycocalyx

scholarly journals Clomiphene Citrate Priming Increases Sensitivity During Ovarian Stimulation in Poor Ovarian Responders Undergoing In Vitro Fertilization Treatment: A Retrospective Cohort Study

2021 ◽  
Author(s):  
Shan Liu ◽  
Xinyu Liu ◽  
Huanhuan Li ◽  
Minghui Liu ◽  
Yasu Lv ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Ovarian Stimulation ◽  
Retrospective Cohort ◽  
Clomiphene Citrate ◽  
Control Group ◽  
Study Group ◽  
Poor Ovarian Responders ◽  
Gonadotropin Dosage ◽  
Antagonist Protocol

Abstract Background: Since ovarian stimulation was introduced as an assisted reproductive technology, poor ovarian response (POR) management has challenged clinicians. Guidance on optimally managing patients with poor response and/or low sensitivity to ovarian stimulation is still lacking. We aimed to investigate whether a clomiphene citrate (CC) priming protocol could increase ovarian sensitivity in poor ovarian responders. Methods: This single-center retrospective cohort study included 294 patients (374 ovarian stimulation cycles). Of these, 193 cycles were treated by a CC priming antagonist protocol (study group) and 181 by the classical flexible gonadotropin-releasing hormone antagonist protocol (control group). Stimulation data and laboratory and clinical outcomes were compared between the groups. Results: Total gonadotropin dosage and dosage per follicle were considerably lower, the follicle-to-oocyte index was significantly higher, and the gonadotropin duration was shorter in the study group. After adjusting for potential confounders, multivariate regression analysis showed that cumulative ongoing pregnancy remained comparable between the groups (adjusted odds ratio: 0.761, 95% confidence interval: 0.300-1.933, P = 0.566). Age, body mass index, gonadotropin dosage per follicle, and the follicle-to-oocyte index were directly associated with the reproductive outcomes. The result of the sensitivity analysis showed that patients stimulated by the CC priming antagonist protocol were administered less gonadotropin (1,739.09 ± 719.39 vs. 3,114.77 ± 1,171.23, P < 0.001) at a lower gonadotropin dosage per follicle (637.36 ± 373.05 vs. 1286.26 ± 976.66, P < 0.001) and for a shorter duration (6.58 ± 2.23 vs. 9.80 ± 1.90, P < 0.001). Conclusions: The CC priming antagonist protocol offered a convenient and patient-friendly way to increase ovarian sensitivity during ovarian stimulation in poor ovarian responders.

Sign in / Sign up

Export Citation Format

Share Document